Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626093 · ClinicalTrials.gov registry record · Phase 4
'Effect of CRT on Defibrillation Threshold Estimates' Study
A Phase 4 study of Sudden Cardiac Death, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 4
- Development phase
- 77
- Enrollment target
- 2
- Study locations
NCT00626093 is a Phase 4 study of Sudden Cardiac Death that has completed, run by Abbott Medical Devices. The registered enrollment target is 77 participants, below the 1,412-participant average among 9 other Sudden Cardiac Death trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00626093, a Phase 4 study of Sudden Cardiac Death, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 77 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this prospective study is to evaluate the effect of cardiac resynchronization therapy (CRT) on the defibrillation threshold (DFT) estimates in cardiac resynchronization therapy defibrillators (CRT-D) patients. The hypothesis of the study is that defibrillation threshold (DFT) will decrease with 6 months of cardiac resynchronization therapy (CRT).
Conditions Studied
Interventions
- DEVICE Cardiac Resynchronization Therapy - Defibrillator (CRT-D)
Study Locations (2)
California
- Pacific Heart Institute - Santa Monica
Colorado
- Penrose Hospital - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626093
The ClinicalTrials.gov registry entry for NCT00626093 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,412-participant average among 9 other Sudden Cardiac Death trials with a reported enrollment target (95% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sudden Cardiac Death appearing as the primary indexed condition, and to 1 intervention - of which Cardiac Resynchronization Therapy - Defibrillator (CRT-D) is the first listed.
NCT00626093 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00626093 about?
NCT00626093 is a clinical study titled "'Effect of CRT on Defibrillation Threshold Estimates' Study". The purpose of this prospective study is to evaluate the effect of cardiac resynchronization therapy (CRT) on the defibrillation threshold (DFT) estimates in cardiac resynchronization therapy defibrillators (CRT-D) patients. The hypothesis of the study is that defibrillation threshold (DFT) will dec...
What is the current status of trial NCT00626093?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 77 participants. The study started on 2008-01. Estimated completion is 2010-04.
What conditions does trial NCT00626093 study?
This clinical trial studies the following conditions: Sudden Cardiac Death.
What interventions are being tested in trial NCT00626093?
The interventions under investigation include: Cardiac Resynchronization Therapy - Defibrillator (CRT-D) (DEVICE).
Who is sponsoring clinical trial NCT00626093?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00626093 being conducted?
This trial has 2 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sudden Cardiac Death
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
RECRUITING · Phase 4
-
Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications
COMPLETED · Phase 4
-
Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk
RECRUITING
-
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
RECRUITING · NA
-
Mayo AVC Registry and Biobank
RECRUITING
-
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.